Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02440009

A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis — RIA  

Allergic Bronchopulmonary Aspergillosis Clinical Trial

Official title:
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis

Clinical Trial Summary

The study evaluates the addition of itraconazole to glucocorticoids in management of acute stages of allergic bronchopulmonary aspergillosis (ABPA). Half of the participants will receive glucocorticoids while the other half will receive itraconazole and glucocorticoids

Clinical Trial Description

The management of allergic bronchopulmonary aspergillosis (ABPA) includes two important aspects namely institution of immunosuppressive therapy in the form of glucocorticoids to control the immunologic activity, and close monitoring for detection of relapses. Another possible target is to use antifungal agents to attenuate the fungal burden secondary to the fungal colonization in the airways. Oral corticosteroids are currently the treatment of choice for ABPA associated with bronchial asthma. They not only suppress the immune hyperfunction but are also anti-inflammatory. Itraconazole, an oral triazole with relatively low toxicity, is active against Aspergillus spp. in vitro and in vivo. The activity of itraconazole against Aspergillus spp. is more than that of ketoconazole. The administration of itraconazole can eliminate Aspergillus in the airways and can theoretically reduce the allergic responses in ABPA. We hypothesize that itraconazole when given in the acute stages of ABPA will decrease the chances of relapse and progression to glucocorticoid-dependent ABPA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02440009
Study type Interventional
Source Postgraduate Institute of Medical Education and Research
Contact
Status Completed
Phase Phase 2/Phase 3
Start date May 2014
Completion date July 31, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT01222273 - Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis N/A
Completed NCT04442269 - Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Phase 2
Terminated NCT00787917 - An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Phase 4
Completed NCT02273661 - Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). Phase 2
Not yet recruiting NCT05129033 - A Prospective Study on Optimizing Treatment for ABPA N/A
Completed NCT01857479 - A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Not yet recruiting NCT06244979 - iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Phase 2
Completed NCT00585364 - Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA N/A
Completed NCT01621321 - Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Recruiting NCT05444946 - Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome N/A
Terminated NCT03960606 - Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis Phase 2
Active, not recruiting NCT04227483 - Deflazacort vs. Prednisolone in Acute-stage ABPA Phase 2/Phase 3
Withdrawn NCT05903612 - Allergic Bronchopulmonary Aspergillosis Prescreening Study
Completed NCT04229303 - Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Phase 1
Completed NCT04476758 - Immune Profiles in CF Fungal Infection
Withdrawn NCT04108962 - Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Phase 4
Recruiting NCT06174922 - A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis Phase 3
Completed NCT01321827 - Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT00974766 - Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3